Roche Acquires Rights to Alzheimer’s Drug From AC Immune

Roche Holding AG bought the rights to an experimental drug for Alzheimer’s disease from closely held AC Immune, its second deal with the Swiss company.

Roche’s Genentech unit will pay an undisclosed amount for rights to AC Immune’s anti-Tau antibodies, plus more than 400 million Swiss francs ($421 million) if the drugs meet targets, Lausanne-based AC Immune said in a statement today. Roche will also pay royalties on sales of the treatments.